Natixis Advisors LLC Has $5.47 Million Stock Position in Natera, Inc. $NTRA

Natixis Advisors LLC lowered its position in shares of Natera, Inc. (NASDAQ:NTRA) by 33.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 23,884 shares of the medical research company’s stock after selling 12,166 shares during the period. Natixis Advisors LLC’s holdings in Natera were worth $5,472,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 9.4% during the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after buying an additional 1,003,129 shares in the last quarter. State Street Corp lifted its holdings in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after buying an additional 72,087 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after buying an additional 727,366 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Natera by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock worth $596,078,000 after buying an additional 11,689 shares in the last quarter. Finally, Fred Alger Management LLC lifted its holdings in shares of Natera by 1.7% during the third quarter. Fred Alger Management LLC now owns 2,451,779 shares of the medical research company’s stock worth $394,663,000 after buying an additional 41,303 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insiders Place Their Bets

In related news, insider John Fesko sold 1,688 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $204.10, for a total value of $344,520.80. Following the completion of the transaction, the insider owned 187,511 shares of the company’s stock, valued at $38,270,995.10. The trade was a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,405 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $203.69, for a total value of $693,564.45. Following the completion of the transaction, the insider directly owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This trade represents a 2.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 148,500 shares of company stock valued at $32,274,898 over the last 90 days. 5.05% of the stock is owned by company insiders.

Natera Stock Down 0.9%

NTRA stock opened at $213.47 on Tuesday. The company has a market cap of $30.57 billion, a PE ratio of -130.96 and a beta of 1.56. The business has a 50-day simple moving average of $204.53 and a 200 day simple moving average of $216.13. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $256.36.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on NTRA. Evercore reissued an “outperform” rating and set a $270.00 target price on shares of Natera in a report on Friday, May 8th. Morgan Stanley dropped their target price on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. BTIG Research dropped their target price on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a report on Monday, May 11th. Wolfe Research began coverage on Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their target price on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and an average target price of $256.12.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.